These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 9128317)

  • 1. A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
    Lerang F; Moum B; Ragnhildstveit E; Haug JB; Hauge T; Tolås P; Aubert E; Henriksen M; Efskind PS; Nicolaysen K; Søberg T; Odegaard A; Berge T
    Am J Gastroenterol; 1997 Apr; 92(4):653-8. PubMed ID: 9128317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
    Lerang F; Moum B; Haug JB; Tolås P; Breder O; Aubert E; Høie O; Søberg T; Flaaten B; Farup P; Berge T
    Am J Gastroenterol; 1997 Feb; 92(2):248-53. PubMed ID: 9040200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
    Thijs JC; van Zwet AA; Moolenaar W; Wolfhagen MJ; ten Bokkel Huinink J
    Am J Gastroenterol; 1996 Jan; 91(1):93-7. PubMed ID: 8561152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.
    Lerang F; Moum B; Ragnhildstveit E; Sandvei PK; Tolås P; Whist JE; Henriksen M; Haug JB; Berge T
    Am J Gastroenterol; 1998 Feb; 93(2):212-6. PubMed ID: 9468244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
    Tefera S; Berstad A; Bang CJ; Nysaeter G; Hatlebakk JG; Olafsson S; Nesje LB; Hausken T; Berstad K; Hundal O
    Am J Gastroenterol; 1996 May; 91(5):935-41. PubMed ID: 8633584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
    van der Wouden EJ; Thijs JC; van Zwet AA; Kooy A; Kleibeuker JH
    Am J Gastroenterol; 1998 Aug; 93(8):1228-31. PubMed ID: 9707042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study.
    Saberi-Firoozi M; Massarrat S; Zare S; Fattahi M; Javan A; Etaati H; Dehbashi N
    Am J Gastroenterol; 1995 Sep; 90(9):1419-23. PubMed ID: 7661161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
    Labenz J; Stolte M; Peitz U; Tillenburg B; Köhl H; Becker T; Börsch G
    Z Gastroenterol; 1995 Oct; 33(10):590-3. PubMed ID: 7502551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
    Kayser S; Flury R; Zbinden R; Fried M; Wirth HP
    Schweiz Med Wochenschr; 1997 Apr; 127(17):722-7. PubMed ID: 9221483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
    Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
    Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
    de Boer WA; Haeck PW; Otten MH; Mulder CJ
    Am J Gastroenterol; 1998 Jul; 93(7):1101-7. PubMed ID: 9672338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing.
    Forné M; Viver JM; Esteve M; Fernández-Bañares F; Lite J; Espinós JC; Quintana S; Salas A; Garau J
    Am J Gastroenterol; 1998 Jan; 93(1):35-8. PubMed ID: 9448170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
    Bago J; Halle ZB; Strinić D; Kućisec N; Jandrić D; Bevanda M; Tomić M; Bilić A
    Wien Klin Wochenschr; 2002 Jun; 114(12):448-53. PubMed ID: 12422579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers.
    Sung JJ; Leung VK; Chung SC; Ling TK; Suen R; Cheng AF; Li AK
    Am J Gastroenterol; 1995 Sep; 90(9):1424-7. PubMed ID: 7661162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer.
    Tzivras M; Archimandritis A; Balatsos V; Delis V; Souyioultzis S; Skandalis N; Kanellopoulou E; Manika Z; Davaris P
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1185-9. PubMed ID: 9471024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.